1. What is HR-positive/HER2-negative Breast Cancer? HR-positive or HER2-negative breast cancer is the commonest carcinoma and also accounts for a better percentage of all breast cancers. HR-positive cancer is typically treated with hormone therapies or a combination of hormone therapies with targeted therapy to assist stop tumor growth. DelveInsight's new launch on "HR-positive/HER2-negative breast cancer Market report 2030” delivers an in-depth understanding of the HR-positive/HER2-negative breast cancer, historical and forecasted epidemiology also because the HR-positive/HER2-negative breast cancer market trends within the 7MM. HR-positive/HER2-negative Breast Cancer Diagnosis The diagnosis of carcinoma depends on the presentation of the lesion by mammographic screening, other radiological imaging, or by a physical presence. Altogether cases, it's vital to mix the radiologic assessment of the whole affected breast and thus the contralateral breast with the overall health hormone therapies or a mixture of hormone therapies with targeted therapy to assist stop tumor growth. HR-positive/HER2-negative Breast Cancer Treatment Options HR-positive/HER2-negative breast cancer treatments are as follows: ● Everolimus (Afinitor) ● Alpelisib (Piqray) ● Fulvestrant (Faslodex) ● Tamoxifen

2. ● Toremifene (Fareston) ● Goserelin (Zoladex) and leuprolide (Lupron) ● Monoclonal antibodies ● Antibody-drug conjugates (ADC) ● Kinase inhibitors The HR-positive/HER2-negative Breast Cancer market report 2030 provides HR-positive/HER2- negative Breast Cancer treatment algorithms and therapies in the 7mm. HR-positive/HER2-negative Breast Cancer Epidemiology Insights Hormone receptors are proteins that receive signals and initiate the cancer cells to grow. If carcinoma cells get signals from the hormone estrogen that might promote tumor growth, it's mentioned as estrogen receptor-positive (ER+) carcinoma. Breast cancer that's ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Carcinoma cells may have one, both, or none of these receptors. Key Insights: ●The total incident population of breast cancer within the 7MM is estimated to be 631,014 in 2018. ●Estimates show that the highest prevalent population of breast cancer is within the United States. DelveInsight’s estimates suggest that supported the stage-specific incidence of breast cancer in postmenopausal women, Stage IIIb,c, and IV-specific breast cancer patients were observed to be less in number as compared to Stage I–IIIa. This section of the DelveInsight HR-positive/HER2-negative Breast Cancer report also includes information on the diagnosed patient pool, trends, and assumptions used. For each of the seven major countries, the HR-positive/HER2-negative Breast Cancer epidemiology section provides information on historical and present HR-positive/HER2-negative Breast Cancer patient pools, as well as predicted trends. HR-positive/HER2-negative Breast Cancer Market Insights Breast Cancer may be a highly heterogeneous disease, and its successful management reflects a multidisciplinary approach, which needs both local disease control and tailored systemic adjuvant therapy. Estrogen receptor (ER) expression is the main indicator of potential responses to hormonal therapy, and most human Breast Cancers are hormone-dependent and ER-Positive. Several classes of anti-estrogenic agents available for patients with early, advanced, or metastatic carcinoma include selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptors, degrader. Key Insights:

3. ●The postmenopausal breast cancer market size within the 7MM was found to be USD 6,315.1 million in 2018. ●The HR-positive/HER2-negative Breast Cancer market size shall increase during the forecast period 2021–2030. ●Among the 7MM, the US accounts for 80.51% USD of the HR-positive/HER2-negative Breast Cancer market size in 2018. ●Among the EU5 countries, Germany accounts for the highest HR-positive/HER2-negative Breast Cancer market size followed by France, Italy, the UK, and Spain. According to DelveInsight, the HR-positive/HER2-negative Breast Cancer Market in 7MM is expected to change in the study period 2017-2030. HR-positive/HER2-negative Breast Cancer Emerging Therapy Assessment ●SHR6390 : Jiangsu HengRui Medicine ●Elacestrant (RAD1901): Radius Pharmaceuticals ●Sacituzumab govitecan : Immunomedics ●Ipatasertib and Venclexta : Roche ●Entinostat: Syndax Pharmaceuticals ●Pembrolizumab: Merck Sharp and Dohme ●Eribulin Mesylate: Merck Sharp and Dohme Corp./Eisai ●Radium-223 dichloride: Bayer ●And others. SHR6390 by Jiangsu HengRui Medicine SHR6390 is cyclin-dependent kinases 4 and 6 (CDK4/6) under development by Jiangsu HengRui Medicine, which may be a key component of cell cycle progression and is dysregulated in cancers. Elacestrant (RAD1901) by Radius Pharmaceuticals Elacestrant (RAD1901) is an investigational product by Radius Pharmaceutical. The drug might be a selective estrogen receptor degrader (SERD), for potential use within the treatment of hormone-receptor- positive carcinoma. Sacituzumab govitecan by Immunomedics Sacituzumab govitecan (IMMU-132) is a complicated product candidate, which is a novel, first-in-class antibody-drug conjugate (ADC). Ipatasertib and Venclexta By Roche Ipatasertib (GDC-0068, RG7440) may be a small molecule pan-Akt inhibitor. it is a PI3K/Akt/mTOR pathway that regulates cell growth and survival. GDC-0068 binds to and blocks the activation of AKT, which finishes up in cell cycle arrest, inhibition of tumor cell proliferation, and induction of tumor cell death. Pembrolizumab by Merck Sharp and Dohme Pembrolizumab (MK-3475) is a humanized antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Pembrolizumab is an IgG4 kappa immunoglobulin, with a relative molecular mass of 149 kDa. The asset is in phase II clinical trials of clinical development. The emerging therapy assessment segment of the HR-positive/HER2-negative breast cancer report encloses an in-depth analysis of HR-positive/HER2-negative breast cancer marketed drugs and late- stage pipeline drugs.